---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-008518"
form_type: "8-K"
ticker: "BFRG"
cik: "0001829247"
company_name: "BullFrog AI Holdings, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:32:57.237573+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bullfrog AI enters collaboration with Eleison to optimize Phase 3 pancreatic cancer trial

## Summary
- Collaboration announced Feb 27, 2025; Bullfrog AI to apply bfLEAP platform to Eleison's glufosfamide Phase 3 trial.
- Bullfrog Data Networks will analyze safety signals and extract predictive biomarkers from prior and ongoing studies.
- Eleison's ongoing glufosfamide Phase 3 trial targets second-line pancreatic cancer; expected completion in 2027.
- Financial terms of the agreement were not disclosed.
- Partnership also covers Eleison's pipeline programs ILC (lung cancer) and DBD (brain cancers).

## SEC filing metadata
- accession: 0001493152-25-008518
- form_type: 8-K
- ticker: BFRG
- cik: 0001829247
- company_name: BullFrog AI Holdings, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829247/000149315225008518/0001493152-25-008518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829247/000149315225008518/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-008518
- JSON: https://secwatch.observer/filing/0001493152-25-008518.json
- Plain text: https://secwatch.observer/filing/0001493152-25-008518.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.